Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.
BACKGROUND Chronic kidney disease ( CKD ) is associated with inflammation . The effects of atorvastatin on biomarkers of inflammation were assessed in CKD patients in the LORD trial . METHODS 117 patients with serum creatinine > 120 μmol/L were r and omized to receive atorvastatin 10 mg/day ( 56 ) or placebo ( 61 ) and followed for a mean of 2.5 years . 33 individuals with normal kidney function were controls . Outcomes included comparison of changes in pentraxin-3 ( PTX3 ) , TNF-α , CRP , IL-6 , IL-8 , and IL-10 between atorvastatin and placebo-treated patients . RESULTS At baseline , compared with controls , CKD patients had increased PTX3 ( mean , 1.08 vs. 0.58 ng/mL ; p < 0.001 ) , CRP ( 4.9 vs. 1.5 mg/L ; p < 0.001 ) , IL-8 ( 6.00 vs. 4.58 pg/mL ; p = 0.001 ) , IL-10 ( 59.0 vs. 17.6 pg/mL ; p = 0.007 ) , and TNF-α ( 18.0 vs. 5.6 ng/mL ; p < 0.001 ) . In patients with raised baseline plasma IL-6/8/10 and /or PTX3 the eGFR decline during the trial was significantly less in those treated with atorvastatin compared to placebo ( mean change , -3.36 ; vs. + 1.25 mL/min/1.73 m2/year ; difference , 4.61 95 % CI 0.98 - 8.25 ; p = 0.002 ) , whilst those without raised inflammatory biomarkers showed no difference . Placebo treated patients with raised TNF-α levels had no eGFR decline ( p > 0.90 ) , whereas in atorvastatin-treated patients eGFR declined ( p = 0.05 ) . CONCLUSIONS CKD patients with inflammation treated with atorvastatin had significantly less eGFR decline . Larger studies using statin therapy , specifically enrolling CKD patients with inflammation , may be worthwhile exploring
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .